[Differences of characteristics and outcomes between cancer patients and patients with no active cancer hospitalised for a SARS-CoV-2 infection]
Charlotte Fenioux, Yves Allenbach, Aurore Vozy, Joe-Élie Salem, Georgina Maalouf, Matheus Vieira, Alexandre Le Joncour, Olivier Benveniste, David Saadoun, Corinne Frère, Luca Campedel, Pierre Salem, Joseph Gligorov, Christian Funck-Brentano, Patrice Cacoub, Paul Gougis, Charlotte Fenioux, Yves Allenbach, Aurore Vozy, Joe-Élie Salem, Georgina Maalouf, Matheus Vieira, Alexandre Le Joncour, Olivier Benveniste, David Saadoun, Corinne Frère, Luca Campedel, Pierre Salem, Joseph Gligorov, Christian Funck-Brentano, Patrice Cacoub, Paul Gougis
Abstract
Background: Patients with solid cancer or haematologic malignancies have been considered to be more susceptible to SARS-CoV-2 infection and to more often develop severe complications. We aimed to compare the differences in clinical features and outcomes of COVID-19 patients with and without cancer.
Methods: This was a prospective observational cohort study of consecutive adult patients hospitalised in a COVID-19 unit at Pitié-Salpêtrière Hospital, Paris, France (NCT04320017).
Results: Among the 262 patients hospitalised in a medical ward during the pandemics with a confirmed COVID-19 diagnosis, 62 patients had cancer. Clinical presentation, comorbidities, and outcomes were similar between cancer and non-cancer patients. However, cancer patients were more likely to have been contaminated while being hospitalised.
Conclusions: Oncologic and non-oncologic patients hospitalised for COVID-19 shared similar outcomes in terms of death, admission in intensive care, or thrombosis/bleeding. They should benefit from the same therapeutic strategy as the general population during the COVID-19 pandemic.
Keywords: COVID-19; Cancer; Cardiovascular complications; Complications cardio-vasculaires.
Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.
References
- Liang W., Guan W., Chen R. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–337.
- Zhang L., Zhu F., Xie L. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020 doi: 10.1016/j.annonc.2020.03.296.
- Lee L.Y.W., Cazier J.B., Starkey T. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020 doi: 10.1016/S0140-6736(20)31173-9.
- Yang K., Sheng Y., Huang C. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020 doi: 10.1016/S1470-2045(20)30310-7.
- Heus P., Damen J.A.A.G., Pajouheshnia R. Uniformity in measuring adherence to reporting guidelines: the example of TRIPOD for assessing completeness of reporting of prediction model studies. BMJ Open. 2019:9. doi: 10.1136/bmjopen-2018-025611.
- Prokop M., van Everdingen W., van Rees Vellinga T. CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation. Radiology. 2020;296:E97–E104.
- El-Shakankery K.H., Kefas J., Crusz S.M. Caring for our cancer patients in the wake of COVID-19. Br J Cancer. 2020;123:3–4.
- RECOVERY Collaborative Group, Horby P., Lim W.S. Dexamethasone in hospitalized patients with Covid-19 – preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436.
- Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–2040.
- Patell R., Bogue T., Bindal P. Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19. J Thromb Haemost. 2020 doi: 10.1111/jth.15018.
- Kuderer N.M., Choueiri T.K., Shah D.P. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918.
- Gougis P., Fenioux C., Funck-Brentano C. Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: what can we safely use? Eur J Cancer. 2020;136:1–3.
Source: PubMed